anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Time after time studies find that often, even when administered by trained professionals, cardiopulmonary resuscitation (CPR) compression rates and depth are inadequate. Too week, shallow or too forceful compressions may contribute to suboptimal patient outcome. Several parameters are crucial for optimal and properly-administered CPR. Crucial parameters include proper hand positioning on the patient's chest, depth of compression of 4-5 cm, and compression rate of 100 compressions per minute. The crucial parameters are often affected by patient parameters, and relative to the patient, rescuer parameters, such as patient thoracic volume; weight; age; gender; and rescuer's, relative to the patient's, parameters, such as weight, height; physical form, etc. Proposed is an automated CPR feedback device with user programmable settings for assisting with real-time feedback and subsequently correcting rescuers patient customized CPR technique.
BACKGROUND: Polygonatum kingianum Coll. & Hemsl (PK), a prominent medicine and food homology plant, has been consumed as a decoction from boiling water for thousands of years. 'Nine Steaming Nine Sun-drying' processing has been considered an effective method for enriching tonic properties, but studies investigating such impacts on PK and underlying mechanisms are extremely rare.
RESULTS: We first demonstrated substantial improvements in the anti-oxidative, anti-inflammatory and anti-hyperglycemia effects of the Nine Steaming Nine Sun-drying processed PK water extracts compared with crude PK in cell models (i.e., HepG2 and Raw 264.7 cells). We then integrated foodomics and network pharmacology analysis to uncover the key compounds responsible for the improved benefits. A total of 551 metabolites of PK extracts were identified, including polyphenols, flavonoids, alkaloids, and organic acids. During processing, 204 metabolites were enhanced, and 32 metabolites were recognized as key constituents of processed PK responsible for the improved health-promoting activities, which may affect PI3K-Akt-, MAPK-, and HIF-1 pathways. We further confirmed the high affinity between identified key constituents of processed PK and their predicted acting targets using molecular docking.
CONCLUSION: Our results provide novel insights into bioactive compounds of processed PK, elaborating the rationality of processing from the perspective of tonic effects. Consuming processed PK could be an efficacious strategy to combat the high prevalence of metabolic diseases that currently affect millions of people worldwide. © 2023 Society of Chemical Industry.
Strategy 2 of antimicrobial stewardship: Prescription of antimicrobial agents are audited 48-72 hours later by infectious diseases physician consultant. Use allowed without authorization for 72 hours.
Diagnostic overshadowing refers to a phenomenon whereby people with mental health conditions encounter inadequate or delayed medical attention and misdiagnosis. This occurs when physical symptoms are mistakenly attributed to their mental health condition. This paper presents a scoping review focusing on direct causes and background factors of diagnostic overshadowing in the context of hepatitis C infection in people who inject drugs and have concurrent mental health conditions. Despite significant strides in hepatitis C treatment with direct-acting antiviral drugs, the complex interplay of mental health conditions and physical symptoms necessitates a nuanced approach for accurate diagnosis and effective screening. This review was conducted using Joanna Briggs Institute's methodology for scoping reviews. The databases searched included Medline, Embase, PsycInfo, Global Health, CINAHL and Scopus. This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). The search strategies identified 1995 records. Overall, 166 studies were excluded. Forty-two (42) studies met the inclusion criteria. Three (n = 3) studies represented direct causes, and 39 (n = 39) with background factors related to diagnostic overshadowing. Studies highlighted six key themes encompassing diagnostic overshadowing, with communication barriers, stigma and knowledge deficiencies being the most prominent. Recognising and addressing diagnostic overshadowing in chronic hepatitis C will lead to increased screening, diagnosis and timely administration of life-saving antiviral therapy, resulting in profound enhancements in well-being and health outcomes. Moreover, this proactive approach will play a pivotal role in advancing the global effort towards eliminating hepatitis C by 2030.
Fetal growth restriction (FGR) is associated with cardiovascular and respiratory complications after birth and beyond. Despite research showing a range of neurological changes following FGR, little is known about how FGR affects the brainstem cardiorespiratory control centres. The primary neurons that release serotonin reside in the brainstem cardiorespiratory control centres and may be affected by FGR. At two time points in the last trimester of sheep brain development, 110 and 127 days of gestation (0.74 and 0.86 of gestation), we assessed histopathological alterations in the brainstem cardiorespiratory control centres of the pons and medulla in early-onset FGR versus control fetal sheep. The FGR cohort were hypoxaemic and asymmetrically growth restricted. Compared to the controls, the brainstem of FGR fetuses exhibited signs of neuropathology, including elevated cell death and reduced cell proliferation, grey and white matter deficits, and evidence of oxidative stress and neuroinflammation. FGR brainstem pathology was predominantly observed in the medullary raphé nuclei, hypoglossal nucleus, nucleus ambiguous, solitary tract and nucleus of the solitary tract. The FGR groups showed imbalanced brainstem serotonin and serotonin 1A receptor abundance in the medullary raphé nuclei, despite evidence of increased serotonin staining within vascular regions of placentomes collected from FGR fetuses. Our findings demonstrate both early and adaptive brainstem neuropathology in response to placental insufficiency. KEY POINTS: Early-onset fetal growth restriction (FGR) was induced in fetal sheep, resulting in chronic fetal hypoxaemia. Growth-restricted fetuses exhibit persistent neuropathology in brainstem nuclei, characterised by disrupted cell proliferation and reduced neuronal cell number within critical centres responsible for the regulation of cardiovascular and respiratory functions. Elevated brainstem inflammation and oxidative stress suggest potential mechanisms contributing to the observed neuropathological changes. Both placental and brainstem levels of 5-HT were found to be impaired following FGR.
Currently, second-line treatment options for advanced HCC (aHCC) patients including single TKI or anti-PD-(L)1 remains limited survival benefits and objective responses. To explore more effective and safer second-line or later therapies for aHCC is necessary. Cadonilimab is a first-in-class humanized IgG1 bispecific antibody that binds to PD-1 and CTLA-4 simultaneously. Dual checkpoint inhibition of the PD-1 and CTAL4 pathways with single cadonilimab has the potential to boost immune surveillance in HCC. Previously data indicated that cadonilimab possesses an encouraging anti-tumour activity and an improved safety profile compared to the co-administration of anti-PD-1 plus anti-CTLA-4 antibodies. Regorafenib is a TKI and approved for second-line treatment of uHCC globally. Here, the investigators evaluated the safety of cadonilimab plus regorafenib as second-line or later therapy in patients with aHCC.
Formerly regarded as a rare disease, bronchiectasis is increasingly recognised. A renewed interest in this disease has led to significant progress in bronchiectasis research. Randomised clinical trials (RCTs) have demonstrated the benefits of airway clearance techniques, inhaled antibiotics and long-term macrolide therapy in bronchiectasis patients. However, the heterogeneity of bronchiectasis remains one of the most challenging aspects of management. Phenotypes and endotypes of bronchiectasis have been identified to help find "treatable traits" and partially overcome disease complexity. The goals of therapy for bronchiectasis are to reduce the symptom burden, improve quality of life, reduce exacerbations and prevent disease progression. We review the pharmacological and non-pharmacological treatments that can improve mucociliary clearance, reduce airway inflammation and tackle airway infection, the key pathophysiological features of bronchiectasis. There are also promising treatments in development for the management of bronchiectasis, including novel anti-inflammatory therapies. This review provides a critical update on the management of bronchiectasis focusing on treatable traits and recent RCTs.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes new estra-1,3,5(10)- -triene sulfamates of the general formula (I)   where R means the group R 1 R 2 N where R 1  and R 2  means independently hydrogen atom or C 1 -C 5 -alkyl group or in common with nitrogen atom form polymethyleneimino-group containing 4-6 carbon atoms or morpholino-group; R 3  means hydrogen atom or C 1 -C 5 -alkyl group; R 4  means hydrogen atom, hydroxyl group, esterified hydroxyl group, halogenalkyl group containing 1-5 carbon atoms or alkoxy-group contaning 1-5 carbon atoms; R 5  and R 6  each means hydrogen atom or in common means methylene group; R 7 , R 8  and R 9  mean independently each of other hydrogen atom or hydroxyl group and ring B can has one or two double bonds, or R 8  means alkynyl residue containing up to 5 carbon atoms, or R 8  and R 9  in common can mean oxygen atom in the case when at least one of residues R 3 , R 4 , R 5 , R 6  or R 7  is not hydrogen atom. Compounds can be used for the hormonal contraception and substituent therapy of climacteric hormone (HRT) and for treatment of patients with gynecological and andrological illnesses. Compounds show low estrogenicite effect on the liver. Invention describes also methods of synthesis of compounds and pharmaceutical compositions preparing. EFFECT: improved method of synthesis and preparing, enhanced hormonal effectiveness. 4 cl, 1 tbl, 26 ex
PURPOSE: To explore the application value of a multimodal deep learning radiomics (MDLR) model in predicting the risk status of postoperative progression in solid stage I non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS: A total of 459 patients with histologically confirmed solid stage I NSCLC who underwent surgical resection in our institution from January 2014 to September 2019 were reviewed retrospectively. At another medical center, 104 patients were reviewed as an external validation cohort according to the same criteria. A univariate analysis was conducted on the clinicopathological characteristics and subjective CT findings of the progression and non-progression groups. The clinicopathological characteristics and subjective CT findings that exhibited significant differences were used as input variables for the extreme learning machine (ELM) classifier to construct the clinical model. We used the transfer learning strategy to train the ResNet18 model, used the model to extract deep learning features from all CT images, and then used the ELM classifier to classify the deep learning features to obtain the deep learning signature (DLS). A MDLR model incorporating clinicopathological characteristics, subjective CT findings and DLS was constructed. The diagnostic efficiencies of the clinical model, DLS model and MDLR model were evaluated by the area under the curve (AUC).
RESULTS: Univariate analysis indicated that size (p = 0.004), neuron-specific enolase (NSE) (p = 0.03), carbohydrate antigen 19 - 9 (CA199) (p = 0.003), and pathological stage (p = 0.027) were significantly associated with the progression of solid stage I NSCLC after surgery. Therefore, these clinical characteristics were incorporated into the clinical model to predict the risk of progression in postoperative solid-stage NSCLC patients. A total of 294 deep learning features with nonzero coefficients were selected. The DLS in the progressive group was (0.721 ± 0.371), which was higher than that in the nonprogressive group (0.113 ± 0.350) (p < 0.001). The combination of size、NSE、CA199、pathological stage and DLS demonstrated the superior performance in differentiating postoperative progression status. The AUC of the MDLR model was 0.885 (95% confidence interval [CI]: 0.842-0.927), higher than that of the clinical model (0.675 (95% CI: 0.599-0.752)) and DLS model (0.882 (95% CI: 0.835-0.929)). The DeLong test and decision in curve analysis revealed that the MDLR model was the most predictive and clinically useful model.
CONCLUSION: MDLR model is effective in predicting the risk of postoperative progression of solid stage I NSCLC, and it is helpful for the treatment and follow-up of solid stage I NSCLC patients.
Placebo is administered intravenously (two doses selected on phase Ib). Each dose level includes up to 6 patients.
This is a prospective, randomized, controlled observer-blind trial measuring the efficacy, safety and immunogenicity of TIV and the safety and immunogenicity of MCV in pregnant women and their infants up to 6 months of age. Women will be recruited in the 3rd trimester of pregnancy and vaccinated with either TIV or MCV. Safety assessments of the women will be completed 30 minutes and 1 week after vaccination, at delivery and 3 and 6 months after delivery. Safety assessments of the infants will be completed at birth and at 3 and 6 months of age. Immunogenicity assessments will include blood sampling of women immediately prior to vaccination, 4 weeks post-vaccination, at delivery and 3 and 6 months after delivery; infants will have cord blood collected at birth and peripheral blood collections at 3 and 6 months of age. Visits to ascertain the costs related to ILI and LCI will also be conducted. The majority of activities conducted in this trial are related to efficacy assessments which will continue until the newborn infant is 6 months of age. We will be conducting case detection for LCI via weekly household visits. In addition, hospital-based surveillance for meningococcal disease will be conducted to measure the efficacy of MCV.
PCT No. PCT/EP87/00126 Sec. 371 Date Oct. 13, 1987 Sec. 102(e) Date Oct. 13, 1987 PCT Filed Mar. 4, 1987 PCT Pub. No. WO87/05500 PCT Pub. Date Sep. 24, 1987.The use of dipropylene glycol monomethyl ether in a quantity of 2 to 25 percent by weight as a swelling and penetrating material in hair shaping compositions based on a keratin softening active ingredient or an oxidizing active ingredient. The use of dipropylene glycol monomethyl ether brings about a clear increase in the effect of hair shaping compositions with an equally good or improved physiological compatibility.
HIV-infected people taking ART have a higher than expected risk of premature CVD. Many factors likely contribute to this risk, including chronic inflammation. Strategies to reduce inflammation in HIV-infected people may be beneficial in reducing CVD risk, as well as other conditions, including kidney disease, bone disease, and neurologic complications. MTX is an anti-inflammatory medication used to treat people with rheumatoid arthritis. This study evaluated the safety and effectiveness of LDMTX at treating inflammation and on endothelial function in virologically suppressed HIV-infected adults who had CVD or were at increased risk of CVD.

The total study duration was 36 weeks. Prior to enrolling in the study, participants had a chest X-ray. Participants were randomly assigned to receive LDMTX or placebo for 24 weeks. Participants continued taking their antiretroviral (ARV) medications as usual; ARVs were not provided by the study. At study entry, participants underwent a medical and medication history, physical examination, blood collection, and adherence assessments. From study entry through Week 1, participants received either 5 mg of LDMTX or placebo once a week. For participants who were clinically stable at the Week 1 study visit, the dose of LDMTX or placebo was increased to 10 mg once a week through Week 12. For participants who were clinically stable at the Week 12 study visit, the dose of LDMTX or placebo was increased to 15 mg once a week through Week 24. Participants who did not meet the criteria for dose escalation were re-evaluated at the following study visit. In addition to LDMTX or placebo, all participants also received 1 mg of folic acid once a day from study entry throughout Week 24. After taking the final dose of LDMTX or placebo, all participants continued taking folic acid for an additional 4 weeks.

Post-entry visits occurred at Weeks 1, 2, 4, 8, 12, 18, 24, and 36. These included a physical examination, blood collection, and adherence assessments; an arm ultrasound test was performed at Weeks 12 and 24. At Week 2, some participants took part in a pharmacokinetic (PK) assessment, which involved undergoing a blood collection several times over a 6-hour period.
PURPOSE: Vision-degrading myodesopsia (VDM) from vitreous floaters significantly degrades vision and impacts visual quality of life (VQOL), but the relationship to light scattering is poorly understood. This study compared in vitro measures of light scatter and transmission in surgically excised human vitreous to preoperative indexes of vitreous structure, visual function, and VQOL.
METHODS: Pure vitreous collected during vitrectomy from 8 patients with VDM had wide-angle straylight measurements and dark-field imaging, performed within 36 hours of vitrectomy. Preoperative VQOL assessment with VFQ-25, contrast sensitivity (CS) measurements with Freiburg acuity contrast testing, and quantitative ultrasonography were compared to light scattering and transmission in vitro.
RESULTS: All indices of vitreous echodensity in vivo correlated positively with straylight at 0.5° (R = 0.708 to 0.775, P = 0.049 and 0.024, respectively). Straylight mean scatter index correlated with echodensity (R = 0.71, P = 0.04) and VQOL (R = -0.82, P = 0.0075). Dark-field measures in vitro correlated with degraded CS in vivo (R = -0.69, P = 0.04). VQOL correlated with straylight mean scatter index (R = -0.823, P = 0.012).
CONCLUSIONS: Increased vitreous echodensity in vivo is associated with more straylight scattering in vitro, validating ultrasonography as a clinical surrogate for light scattering. Contrast sensitivity in vivo is more degraded in the presence of dark-field scattering in vitro and VQOL is decreased in patients whose vitreous has increased light scattering. These findings could form the basis for the development of optical corrections for VDM or support new laser treatments, as well as novel pharmacotherapy.
The present invention provides a skin treating composition comprising caffeine in combination with an adsorbent capable of a retaining an organic waste product or toxin of the skin. The caffeine is an extract from a plant of the genus Coffea or Camellia, and may be present in non¬ aqueous form such as a seed oil. The adsorbent is capable of adsorbing an organic waste product or toxin such as urea, lactate, creatinine, uric acid, ketones, pyruvate, arsenic, cadmium, lead, mercury, zinc, copper, or an environmental contaminant. Adsorbents such as charcoal and zeolite are preferred. The composition may further comprise one or more dermatologically-acceptable excipients and an anionic surfactant. The present compositions are for treatment of the skin of humans for improving the cleanliness, condition and appearance of skin.
FIELD: infectious diseases. SUBSTANCE: mixture of antibiotic and medium- molecular dextran (5 ml 6% polyglucin) is subcutaneously injected into the middle third of medial surface of shin preliminarily anesthetized by 5 ml of 25% novocaine solution. Injection place is then covered by water- alcohol compress for 8-10 hr. In cases of inflammatory infiltration, single dose of antibiotic is administered and, in cases of suppurative process, daily dose. EFFECT: enabled saturation of lymphatic system with antibiotic. 3 cl, 1 tbl
The present invention relates to a composition, including thioredoxin-binding protein (TXNIP) as an active ingredient, for enhancing immunity, inhibiting cancer metastasis, and preventing and treating blood diseases. More specifically, in TXNIP-deficient mice, it is confirmed that the frequency of hematopoietic stem cells and myeloproliferative ability decrease, and that the myeloproliferative ability of marrow cells derived from the TXNIP-deficient mice decreases through bone-marrow transplantation. Moreover, in TXNIP knockout mice and TXNIP-deficient cell strains under oxidative stress conditions, it is confirmed that the level of reactive oxygen species increases and apoptosis is induced, and that the myeloproliferative ability of the cell strains derived from the TXNIP knockout mice decreases. In the TXNIP knockout mice under oxidative stress conditions, it is confirmed that cancer metastasis increases and p53 expression decreases. Moreover, direct binding sites between TXNIP and p53 are identified, and it is confirmed that the binding increases under oxidative stress conditions, thereby increasing p53-mediated transcriptional activities and p53-mediated antioxidant activities. Therefore, a gene carrier, a cell or a TXNIP protein, which includes the TXNIP gene of the present invention can be effectively used as a composition for enhancing immunity, inhibiting cancer metastasis, and preventing and treating blood diseases.
PROBLEM TO BE SOLVED: To obtain the subject composition useful for preventing and treating periodontal diseases without deteriorating the appearance of the composition by including an antioxidant and a collagen compound therein. SOLUTION: This composition is obtained by including (A) an antioxidant (e.g. antioxidant vitamins, polyphenols or a flavonoid compound) and (B) a collagen compound (e.g. a water-soluble collagen, an insoluble collagen, atherocollagen and a hydrolyzable collagen peptide extracted from mammals, fowls and fishes). The amounts of the contained respective ingredients based on the whole composition are preferably 0.0001-5 wt.% ingredient A and 0.001-20 wt.% ingredient B. The objective composition can be formulated into various dosage forms such as a dentifrice, e.g. a toothpaste, a mouthwash, a gingival massaging cream, a topical liniment or a troche.
The invention discloses a liver-regulating impotence-reinvigorating method, and relates to a traditional Chinese medicine pill for treating impotence caused by liver depression and a method for treating impotence under the matching of the pill with acupuncture and moxibustion. According to a technical scheme, the liver-regulating impotence-reinvigorating pill is orally taken under the matching of acupuncture and moxibustion. The liver-regulating impotence-reinvigorating pill contains the following traditional Chinese medicines in proportions: 20% of cordyceps sobolifera, 15% of actinolite, 10% of epimedium, 10% of radix bupleuri, 5% of fructus aurantii, 5% of fingered citron, 5% of white paeony roots, 5% of caltrop, 5% of common curculigo rhizome, 5% of herba epimedii, 5% of roasted centipede, 5% of albizia julibrissin and 5% of cowherb seed. The preparation of the liver-regulating impotence-reinvigorating pill comprises the steps of: evenly stirring and mixing the thirteen traditional Chinese medicines; ultra-finely grinding a mixture; and preparing pills. The liver-regulating impotence-reinvigorating pill is taken with boiled water after a meal and taken for three times per day. During acupuncture and moxibustion, acupoints such as Shenshu, Sanyinjiao Zusanli, and Neiguan Guanyuan Qihai are stimulated moderately, a reinforcing method is adopted, needle retaining is not needed, and moxibustion is implemented after acupuncture. Acupuncture and moxibustion are implemented once per day and meanwhile psychotherapy is implemented.